In this episode, listen to Virginia Kaklamani, MD, DSc; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, share their clinical insights and takeaways from a live symposium, including from key abstracts presented at the 2024 San Antonio Breast Cancer Symposium: Estrogen receptor mutations in patients With HR-positive/HER2-negative advanced breast cancer Current guideline recommendations for when to pursue ESR1 mutation testing mutations in patients with HR-positive/HER2-negative advanced breast cancer Choice and sequencing of next line of systemic therapy for ESR1- mutated advanced breast cancer based on tumor molecular alterations Overview of class-related and unique adverse events with approved and emerging oral SERDS Expert recommendations for the management of oral SERDs-related adverse events Program faculty: Virginia Kaklamani, MD, DSc Professor of Medicine Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment A.B. Alexander Distinguished Chair in Oncology Leader Breast Oncology Program UT Health San Antonio MD Anderson Cancer Center San Antonio, Texas Erica L. Mayer, MD, MPH Director of Breast Cancer Clinical Research Dana-Farber Cancer Institute Associate Professor in Medicine Harvard Medical School Boston, Massachusetts Laura M. Spring, MD Breast Medical Oncologist Mass General Hospital Cancer Center Harvard Medical School Boston, Massachusetts Resources: To download the slides associated with this podcast discussion, please visit the program page . Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
